

All Databases

PubMed

Nucleotide

Protein

Genome

Structure

OMIM

PMC

Journals

Search PubMed



for clark k and AAV



Save S

Limits

Preview/Index

History

Clipboard

Details

Display Summary



Show

20



Sort by .



Send to



About Entrez

Text Version

Entrez PubMed

Overview

Help | FAQ

Tutorial

New/Noteworthy

E-Utilities

PubMed Services

Journals Database

MeSH Database

Single Citation Matcher

Batch Citation Matcher

Clinical Queries

Special Queries

LinkOut

My NCBI (Cubby)

Related Resources

Order Documents

NLM Catalog

NLM Gateway

TOXNET

Consumer Health

Clinical Alerts

ClinicalTrials.gov

PubMed Central

Items 1 - 8 of 8

One page.

☐ 1: [van den Pol AN, Acuna-Goycolea C, Clark KR, Ghosh PK.](#)[Related Articles, Links](#)

Physiological properties of hypothalamic MCH neurons identified with selective expression of reporter gene after recombinant virus infection.

Neuron. 2004 May 27;42(4):635-52.

PMID: 15157424 [PubMed - indexed for MEDLINE]

☐ 2: [Wang C, Wang CM, Clark KR, Sferra TJ.](#)[Related Articles, Links](#)

Recombinant AAV serotype 1 transduction efficiency and tropism in the murine brain.

Gene Ther. 2003 Aug;10(17):1528-34.

PMID: 12900769 [PubMed - indexed for MEDLINE]

☐ 3: [Clark KR.](#)[Related Articles, Links](#)

Recent advances in recombinant adeno-associated virus vector production.

Kidney Int. 2002 Jan;61 Suppl 1:9-15.

PMID: 11841606 [PubMed - as supplied by publisher]

RC902.A1 K5

☐ 4: [Liu X, Voulgaropoulou F, Chen R, Johnson PR, Clark KR.](#)[Related Articles, Links](#)

Selective Rep-Cap gene amplification as a mechanism for high-titer recombinant AAV production from stable cell lines.

Mol Ther. 2000 Oct;2(4):394-403.

PMID: 11020356 [PubMed - indexed for MEDLINE]

☐ 5: [Liu XL, Clark KR, Johnson PR.](#)[Related Articles, Links](#)

Production of recombinant adeno-associated virus vectors using a packaging cell line and a hybrid recombinant adenovirus.

Gene Ther. 1999 Feb;6(2):293-9.

PMID: 10435114 [PubMed - indexed for MEDLINE]

☐ 6: [Clark KR, Liu X, McGrath JP, Johnson PR.](#)[Related Articles, Links](#)

Highly purified recombinant adeno-associated virus vectors are biologically active and free of detectable helper and wild-type viruses.

Hum Gene Ther. 1999 Apr 10;10(6):1031-9.


PMID: 10223736 [PubMed - indexed for MEDLINE]

☐ 7: [Clark KR, Voulgaropoulou F, Johnson PR.](#)[Related Articles, Links](#)

A stable cell line carrying adenovirus-inducible rep and cap genes allows for infectivity titration of adeno-associated virus vectors.

Gene Ther. 1996 Dec;3(12):1124-32.

PMID: 8986439 [PubMed - indexed for MEDLINE]



All Databases

PubMed

Nucleotide

Protein

Genome

Structure

OMIM

PMC

Journals

Search for

Limits

Preview/Index

History

Clipboard

Details

Display

Show

Sort by

Send to

About Entrez

Text Version

Entrez PubMed

Overview

Help | FAQ

Tutorial

New/Noteworthy

E-Utilities

PubMed Services

Journals Database

MeSH Database

Single Citation Matcher

Batch Citation Matcher

Clinical Queries

Special Queries

LinkOut

My NCBI (Cubby)

Related Resources

Order Documents

NLM Catalog

NLM Gateway

TOXNET

Consumer Health

Clinical Alerts

ClinicalTrials.gov

PubMed Central

Items 1 - 6 of 6

One page.

☐ 1: [Liu X, Voulgaropoulou F, Chen R, Johnson PR, Clark KR.](#)[Related Articles, Links](#)**Selective Rep-Cap gene amplification as a mechanism for high-titer recombinant AAV production from stable cell lines.**

Mol Ther. 2000 Oct;2(4):394-403.

PMID: 11020356 [PubMed - indexed for MEDLINE]

☐ 2: [Liu XL, Clark KR, Johnson PR.](#)[Related Articles, Links](#)**Production of recombinant adeno-associated virus vectors using a packaging cell line and a hybrid recombinant adenovirus.**

Gene Ther. 1999 Feb;6(2):293-9.

PMID: 10435114 [PubMed - indexed for MEDLINE]

☐ 3: [Clark KR, Liu X, McGrath JP, Johnson PR.](#)[Related Articles, Links](#)**Highly purified recombinant adeno-associated virus vectors are biologically active and free of detectable helper and wild-type viruses.**

Hum Gene Ther. 1999 Apr 10;10(6):1031-9.

PMID: 10223736 [PubMed - indexed for MEDLINE]

☐ 4: [Lo WD, Qu G, Sferra TJ, Clark R, Chen R, Johnson PR.](#)[Related Articles, Links](#)**Adeno-associated virus-mediated gene transfer to the brain: duration and modulation of expression.**

Hum Gene Ther. 1999 Jan 20;10(2):201-13.

PMID: 10022545 [PubMed - indexed for MEDLINE]

☐ 5: [Clark KR, Voulgaropoulou F, Johnson PR.](#)[Related Articles, Links](#)**A stable cell line carrying adenovirus-inducible rep and cap genes allows for infectivity titration of adeno-associated virus vectors.**

Gene Ther. 1996 Dec;3(12):1124-32.

PMID: 8986439 [PubMed - indexed for MEDLINE]

☐ 6: [Clark KR, Voulgaropoulou F, Fraley DM, Johnson PR.](#)[Related Articles, Links](#)**Cell lines for the production of recombinant adeno-associated virus.**

Hum Gene Ther. 1995 Oct;6(10):1329-41.

PMID: 8590738 [PubMed - indexed for MEDLINE]



Display

Show

Sort by

Send to

[Write to the Help Desk](#)[NCBI | NLM | NIH](#)[Department of Health & Human Services](#)[Privacy Statement | Freedom of Information Act | Disclaimer](#)



All Databases

PubMed

Nucleotide

Protein

Genome

Structure

OMIM

PMC

Journals

 Search for

Limits

Preview/Index

History

Clipboard

Details

 Display Show Sort by Send to

About Entrez

Text Version

Entrez PubMed

Overview

Help | FAQ

Tutorial

New/Noteworthy

E-Utilities

PubMed Services

Journals Database

MeSH Database

Single Citation Matcher

Batch Citation Matcher

Clinical Queries

Special Queries

LinkOut

My NCBI (Cubby)

Related Resources

Order Documents

NLM Catalog

NLM Gateway

TOXNET

Consumer Health

Clinical Alerts

ClinicalTrials.gov


PubMed Central

All: 14 Review: 0

Items 1 - 14 of 14


One page.

- ☐ 1: [Johnson PR, Schnepf BC, Connell MJ, Rohne D, Robinson S, Krivulka GR, Lord CI, Zinn R, Montefiori DC, Letvin NL, Clark KR.](#) [Related Articles, Links](#)
- Novel adeno-associated virus vector vaccine restricts replication of simian immunodeficiency virus in macaques.
J Virol. 2005 Jan;79(2):955-65.
PMID: 15613324 [PubMed - indexed for MEDLINE]
- ☐ 2: [Schnepf BC, Clark KR, Klemanski DL, Pacak CA, Johnson PR.](#) [Related Articles, Links](#)
- Genetic fate of recombinant adeno-associated virus vector genomes in muscle.
J Virol. 2003 Mar;77(6):3495-504.
PMID: 12610125 [PubMed - indexed for MEDLINE]
- ☐ 3: [Lewis AD, Chen R, Montefiori DC, Johnson PR, Clark KR.](#) [Related Articles, Links](#)
- Generation of neutralizing activity against human immunodeficiency virus type 1 in serum by antibody gene transfer.
J Virol. 2002 Sep;76(17):8769-75.
PMID: 12163597 [PubMed - indexed for MEDLINE]
- ☐ 4: [Liu X, Voulgaropoulou F, Chen R, Johnson PR, Clark KR.](#) [Related Articles, Links](#)
- Selective Rep-Cap gene amplification as a mechanism for high-titer recombinant AAV production from stable cell lines.
Mol Ther. 2000 Oct;2(4):394-403.
PMID: 11020356 [PubMed - indexed for MEDLINE]
- ☐ 5: [Beall CJ, Phipps AJ, Mathes LE, Stromberg P, Johnson PR.](#) [Related Articles, Links](#)
- Transfer of the feline erythropoietin gene to cats using a recombinant adeno-associated virus vector.
Gene Ther. 2000 Mar;7(6):534-9.
PMID: 10757028 [PubMed - indexed for MEDLINE]
- ☐ 6: [Sferra TJ, Qu G, McNeely D, Rennard R, Clark KR, Lo WD, Johnson PR.](#) [Related Articles, Links](#)
- Recombinant adeno-associated virus-mediated correction of lysosomal storage within the central nervous system of the adult mucopolysaccharidosis type VII mouse.
Hum Gene Ther. 2000 Mar 1;11(4):507-19.
PMID: 10724030 [PubMed - indexed for MEDLINE]
- ☐ 7: [Clark KR, Sferra TJ, Lo W, Qu G, Chen R, Johnson PR.](#) [Related Articles, Links](#)

-  Gene transfer into the CNS using recombinant adeno-associated virus: analysis of vector DNA forms resulting in sustained expression.
J Drug Target. 1999 Dec;7(4):269-83.
PMID: 10682906 [PubMed - indexed for MEDLINE]


☐ 8: [Liu XL, Clark KR, Johnson PR.](#)

[Related Articles, Links](#)

-  Production of recombinant adeno-associated virus vectors using a packaging cell line and a hybrid recombinant adenovirus.
Gene Ther. 1999 Feb;6(2):293-9.
PMID: 10435114 [PubMed - indexed for MEDLINE]


☐ 9: [Clark KR, Liu X, McGrath JP, Johnson PR.](#)

[Related Articles, Links](#)

-  Highly purified recombinant adeno-associated virus vectors are biologically active and free of detectable helper and wild-type viruses.
Hum Gene Ther. 1999 Apr 10;10(6):1031-9.
PMID: 10223736 [PubMed - indexed for MEDLINE]


☐ 10: [Lo WD, Qu G, Sferra TJ, Clark R, Chen R, Johnson PR.](#)

[Related Articles, Links](#)

-  Adeno-associated virus-mediated gene transfer to the brain: duration and modulation of expression.
Hum Gene Ther. 1999 Jan 20;10(2):201-13.
PMID: 10022545 [PubMed - indexed for MEDLINE]


☐ 11: [Clark KR, Sferra TJ, Johnson PR.](#)

[Related Articles, Links](#)

-  Recombinant adeno-associated viral vectors mediate long-term transgene expression in muscle.
Hum Gene Ther. 1997 Apr 10;8(6):659-69.
PMID: 9113506 [PubMed - indexed for MEDLINE]


☐ 12: [Clark KR, Voulgaropoulou F, Johnson PR.](#)

[Related Articles, Links](#)

-  A stable cell line carrying adenovirus-inducible rep and cap genes allows for infectivity titration of adeno-associated virus vectors.
Gene Ther. 1996 Dec;3(12):1124-32.
PMID: 8986439 [PubMed - indexed for MEDLINE]


☐ 13: [Clark KR, Voulgaropoulou F, Fraley DM, Johnson PR.](#)

[Related Articles, Links](#)

-  Cell lines for the production of recombinant adeno-associated virus.
Hum Gene Ther. 1995 Oct;6(10):1329-41.
PMID: 8590738 [PubMed - indexed for MEDLINE]

☐ 14: [Chatterjee S, Johnson PR, Wong KK Jr.](#)



[Related Articles, Links](#)

-  Dual-target inhibition of HIV-1 in vitro by means of an adeno-associated virus antisense vector.
Science. 1992 Nov 27;258(5087):1485-8.
PMID: 1359646 [PubMed - indexed for MEDLINE]

Display  Show  Sort by  Send to

[Write to the Help Desk](#)
[NCBI | NLM | NIH](#)
[Department of Health & Human Services](#)
[Privacy Statement](#) | [Freedom of Information Act](#) | [Disclaimer](#)

Jun 27 2005 04:57:20



All Databases

PubMed

Nucleotide

Protein

Genome

Structure

OMIM

PMC

Journals

 Search **PubMed** for **clark kr and adeno-associated** **Go** **Clear** **Save S**

Limits

Preview/Index

History

Clipboard

Details

 Display **Summary** Show **20** Sort by Send to

About Entrez

Text Version

Entrez PubMed

Overview

Help | FAQ

Tutorial

New/Noteworthy

E-Utilities

PubMed Services

Journals Database

MeSH Database

Single Citation Matcher

Batch Citation Matcher

Clinical Queries

Special Queries

LinkOut

My NCBI (Cubby)

Related Resources

Order Documents

NLM Catalog

NLM Gateway

TOXNET

Consumer Health

Clinical Alerts

ClinicalTrials.gov










PubMed Central

Items 1 - 15 of 15

One page.

- ☐ 1: [Johnson PR, Schnepf BC, Connell MJ, Rohne D, Robinson S, Krivulka GR, Lord CI, Zinn R, Montefiori DC, Letvin NL, Clark KR.](#) [Related Articles, Links](#)
- Novel adeno-associated virus vector vaccine restricts replication of simian immunodeficiency virus in macaques.
J Virol. 2005 Jan;79(2):955-65.
PMID: 15613324 [PubMed - indexed for MEDLINE]
- ☐ 2: [Wang C, Wang CM, Clark KR, Sferra TJ.](#) [Related Articles, Links](#)
- Recombinant AAV serotype 1 transduction efficiency and tropism in the murine brain.
Gene Ther. 2003 Aug;10(17):1528-34.
PMID: 12900769 [PubMed - indexed for MEDLINE]
- ☐ 3: [Schnepf BC, Clark KR, Klemanski DL, Pacak CA, Johnson PR.](#) [Related Articles, Links](#)
- Genetic fate of recombinant adeno-associated virus vector genomes in muscle.
J Virol. 2003 Mar;77(6):3495-504.
PMID: 12610125 [PubMed - indexed for MEDLINE]
- ☐ 4: [Sun Y, Jin K, Clark KR, Peel A, Mao XO, Chang Q, Simon RP, Greenberg DA.](#) [Related Articles, Links](#)
- Adeno-associated virus-mediated delivery of BCL-w gene improves outcome after transient focal cerebral ischemia.
Gene Ther. 2003 Jan;10(2):115-22.
PMID: 12571640 [PubMed - indexed for MEDLINE]
- ☐ 5: [Lewis AD, Chen R, Montefiori DC, Johnson PR, Clark KR.](#) [Related Articles, Links](#)
- Generation of neutralizing activity against human immunodeficiency virus type 1 in serum by antibody gene transfer.
J Virol. 2002 Sep;76(17):8769-75.
PMID: 12163597 [PubMed - indexed for MEDLINE]
- ☐ 6: [Schnepf B, Clark KR.](#) [Related Articles, Links](#)
- Highly purified recombinant adeno-associated virus vectors. Preparation and quantitation.
Methods Mol Med. 2002;69:427-43. No abstract available.
PMID: 11987793 [PubMed - indexed for MEDLINE]
- ☐ 7: [Clark KR.](#) [Related Articles, Links](#)

Recent advances in recombinant adeno-associated virus vector production.

-  Kidney Int. 2002 Jan;61 Suppl 1:9-15.
PMID: 11841606 [PubMed - as supplied by publisher]
- ☐ **8:** [Liu X, Voulgaropoulou F, Chen R, Johnson PR, Clark KR.](#) Related Articles, Links
 Selective Rep-Cap gene amplification as a mechanism for high-titer recombinant AAV production from stable cell lines.
Mol Ther. 2000 Oct;2(4):394-403.
PMID: 11020356 [PubMed - indexed for MEDLINE]
- ☐ **9:** [Sferra TJ, Qu G, McNeely D, Rennard R, Clark KR, Lo WD, Johnson PR.](#) Related Articles, Links
 Recombinant adeno-associated virus-mediated correction of lysosomal storage within the central nervous system of the adult mucopolysaccharidosis type VII mouse.
Hum Gene Ther. 2000 Mar 1;11(4):507-19.
PMID: 10724030 [PubMed - indexed for MEDLINE]
- ☐ **10:** [Clark KR, Sferra TJ, Lo W, Qu G, Chen R, Johnson PR.](#) Related Articles, Links
 Gene transfer into the CNS using recombinant adeno-associated virus: analysis of vector DNA forms resulting in sustained expression.
J Drug Target. 1999 Dec;7(4):269-83.
PMID: 10682906 [PubMed - indexed for MEDLINE]
- ☐ **11:** [Liu XL, Clark KR, Johnson PR.](#) Related Articles, Links
 Production of recombinant adeno-associated virus vectors using a packaging cell line and a hybrid recombinant adenovirus.
Gene Ther. 1999 Feb;6(2):293-9.
PMID: 10435114 [PubMed - indexed for MEDLINE]
- ☒ **12:** [Clark KR, Liu X, McGrath JP, Johnson PR.](#) Related Articles, Links
 Highly purified recombinant adeno-associated virus vectors are biologically active and free of detectable helper and wild-type viruses.
Hum Gene Ther. 1999 Apr 10;10(6):1031-9.
PMID: 10223736 [PubMed - indexed for MEDLINE]
- ☒ **13:** [Clark KR, Sferra TJ, Johnson PR.](#) Related Articles, Links
 Recombinant adeno-associated viral vectors mediate long-term transgene expression in muscle.
Hum Gene Ther. 1997 Apr 10;8(6):659-69.
PMID: 9113506 [PubMed - indexed for MEDLINE]
- ☐ **14:** [Clark KR, Voulgaropoulou F, Johnson PR.](#) Related Articles, Links
 A stable cell line carrying adenovirus-inducible rep and cap genes allows for infectivity titration of adeno-associated virus vectors.
Gene Ther. 1996 Dec;3(12):1124-32.
PMID: 8986439 [PubMed - indexed for MEDLINE]
- ☐ **15:** [Clark KR, Voulgaropoulou F, Fraley DM, Johnson PR.](#) Related Articles, Links
 Cell lines for the production of recombinant adeno-associated virus.
Hum Gene Ther. 1995 Oct;6(10):1329-41.
PMID: 8590738 [PubMed - indexed for MEDLINE]

Display ☐ Summary ☒ Show ☐ 20 ☒ Sort by ☐ Send to ☒

[Write to the Help Desk](#)

FILE 'MEDLINE, EMBASE, BIOSIS, CAPLUS' ENTERED AT 14:53:47 ON 22 JUL 2005

L1 8149 S AAV OR RAAV OR (ADENO-ASSOCIATED ADJ VIRUS?)
L2 4 S ((REP 78) (S) (REP 68)) OR (REP 78/68) OR ((REP ADJ 78) (2W)
L3 4 DUP REM L2 (0 DUPLICATES REMOVED)
L4 334 S L1 (P) (REP (3A) EXPRESS?)
L5 290 S L4 (P) CELL
L6 129 S L5 (P) HELPER
L7 2 S L6 (P) ((REP 52) OR (REP 40))
L8 8 S L5 (P) ((SIMIAN) OR (SV-20))
L9 2 DUP REM L8 (6 DUPLICATES REMOVED)
L10 99 S L1 (P) ((SIMIAN) OR (SV-20))
L11 42 DUP REM L10 (57 DUPLICATES REMOVED)
L12 11 S L1 (P) ((SIMIAN ADENOVIR?) OR (SV-20))
L13 8 DUP REM L12 (3 DUPLICATES REMOVED)
L14 1 S L1 (P) FRHL?
L15 1 S L1 (P) SV20
L16 1 S L1 (P) PERC.6
L17 2 S L1 (P) MRC-5
L18 2 S L1 AND MRC-5
L19 5 S L1 AND WI-38
L20 5 DUP REM L19 (0 DUPLICATES REMOVED)
L21 47 DUP REM L6 (82 DUPLICATES REMOVED)
L22 10 S L21 AND P5

IN Clark, Kelly Reed; Johnson, Philip R., Jr.

SO PCT Int. Appl., 34 pp.

CODEN: PIXXD2

TI Recombinant adeno-associated virus production using recombinant adenovirus or vaccinia virus expressing AAV rep52 and rep40 gene

AB The present invention relates to methods and materials for recombinant adeno-assocd. virus prodn. More particularly, the invention relates to use of recombinant adenovirus encoding adeno-assocd. virus protein in recombinant adeno-assocd. virus prodn. methods. In contrast to previous methods which rely on decreasing the expression of Rep 78 and 68 proteins, the present inventors contemplate that rAAV can be better produced not by intentionally decreasing expression of Rep 78 and 68 proteins, but instead by intentionally overexpressing Rep 52 and Rep 40 proteins and/or providing supplemental Rep 52 and Rep 40 proteins. The invention thus provides an infectious recombinant adeno-assocd. virus-producing cell that contains a rAAV genome, AAV rep-cap proteins and AAV helper functions and that overexpresses AAV Rep 52 and Rep 40 proteins while expressing AAV Rep 78 and Rep 68 proteins at about the level as if controlled by the p5 promoter in native conformation.

IN Chen, Haifeng; Kurtzman, Gary

SO PCT Int. Appl., 84 pp.

CODEN: PIXXD2

TI Production of recombinant AAV using adenovirus vectors comprising AAV rep/cap genes and use thereof

AB This invention relates to novel adenoviruses useful in the prodn. of high titers of recombinant adeno-assocd. virus (rAAV) comprising a foreign DNA insert and methods of making these adenoviruses. The adenovirus comprises the AAV rep gene in which the p5 promoter of rep is replaced by a minimal promoter or by no promoter. The invention also provides methods of producing high levels of rAAV as a substantially homogeneous prepn. and compns. of rAAV.

AU Kube, Dagmar M.; Ponnazhagan, Selvarangan; Srivastava, Arun [Reprint author]

SO Journal of Virology, (1997) Vol. 71, No. 10, pp. 7361-7371.

CODEN: JOVIAM. ISSN: 0022-538X.

TI Encapsidation of adeno-associated virus type 2 Rep proteins in wild-type and recombinant progeny virions: Rep-mediated growth inhibition of primary human cells.

AB The adeno-associated virus type 2 (AAV) arrests the growth of primary human fibroblasts in vitro at high particle-to-cell ratios. To test the role of AAV gene expression in the observed growth inhibition, primary human cells were infected, under identical conditions,

with wild-type (wt) AAV or with recombinant AAV that lacked all viral promoters and coding sequences. Significant, dose-dependent growth inhibition of primary human cells was observed with both wt and recombinant AAV at particle-to-cell ratios equal to or exceeding 10-4. In contrast, neither virus affected the growth of immortalized human cells even at a 10-fold-higher particle-to-cell ratio. AAV-induced growth arrest could be overcome by reculturing cells after treatment with trypsin. Even after reculturing, cells still harbored the proviral AAV genome. Thus, neither integration nor expression of the AAV genome appears to be required for the virus-induced growth-inhibitory effect on primary human cells. The growth-inhibitory effect of AAV was hypothesized to be mediated by virion-associated AAV Rep proteins, since these proteins have been reported to inhibit cellular DNA synthesis. Rep proteins tightly associated with wt as well as recombinant AAV could be detected on Western blots. Coinfection by adenovirus was necessary and sufficient for ample replication of recombinant AAV genomes lacking the rep gene. Although wt AAV-like particles arose during production of the recombinant AAV stocks, their low-titer levels were insufficient to cause the observed growth inhibition. AAV rep gene expression from these contaminating particles was not required for replication of the recombinant AAV genomes, which could be detected even in the absence of de novo Rep protein synthesis. Exposure of recombinant AAV to anti-AAV Rep protein antibodies did not abrogate viral infectivity. These results suggest that biologically active Rep proteins are encapsulated in mature progeny AAV particles. AAV Rep protein-mediated growth inhibition of primary human cells has implications in the use of AAV-based vectors in human gene therapy.

- IN Flotte, Terence R.; Carter, Barrie J.; Guggino, William B.; Sollow, Rikki
SO PCT Int. Appl., 50 pp.
CODEN: PIXXD2
- TI Generation of high titers of recombinant adeno-associated virus (AAV)
vectors for gene therapy
- AB AAV vectors may have utility for gene therapy but heretofore a significant obstacle has been the inability to generate sufficient quantities of such recombinant vectors in amts. that would be clin. useful for human gene therapy application. Stable, helper-free AAV packaging cell lines have been elusive, mainly due to the activities of Rep protein, which down-regulates its own expression and reverses cellular immortalization. This invention provides packaging systems and processes for packaging AAV vectors that effectively circumvent these problems by replacing the AAV p5 promoter with a heterologous promoter and that allow for substantially increased packaging efficiency. Thus, in packaging plasmid pRS5, the AAV p5 promoter is replaced by a heterologous promoter so that expression of the rep gene polypeptide does not neg. autoregulate its own synthesis; pRS5 contains the entire AAV coding sequence within the AAV nucleotide sequence from nucleotide 263 to 4491 which includes the rep coding sequence for Rep 78 and Rep 68 operably linked to the heterologous HIV-LTR promoter and expresses Rep 52 and Rep 40 from the AAV p19 promoter and the AAV capsid proteins from the p40 promoter. The pAAVp5neo construct was used as a vector construct for testing each of the packaging techniques. Human 293-31 cells were grown in Eagle's Modified Essential Medium with 10% fetal calf serum at 37 deg in 5% CO2. The 293 cell line was used for both packaging of vector prepns. and for neo transduction expts. to verify the neo-transducing titers. The pRS5 construct was used to package the pAAVp5neo vector plasmid by cotransfection into adenovirus type 5 (Ad5)-infected 293 cells. An AAV-CFTR vector, pTRF42, contg. the cystic fibrosis transmembrane conductance regulator cDNA expressed from an AAV ITR as the promoter in the absence of a selectable marker was used to generate stable vector producer lines in the 293 cell line by cotransfection with a pSVneo plasmid. This vector was rescuable from the stable cell lines, and the rescued vector was intact and unrearranged. Examples are given on packaging of AAV vectors encoding CFTR, integration of the lacZ gene into lung airway epithelium, expression of the lacZ gene in mice, and integration and expression of the CD44 gene in lung carcinoma cells.

IN Samulski, Richard J.; Xiao, Xiao; Snyder, Richard
SO PCT Int. Appl., 53 pp.
CODEN: PIXXD2

TI Methods for increasing the efficiency of recombinant adeno-associated virus product

AB High-titer stocks of recombinant adeno-assocd. virus (rAAV) are produced in increased yield by regulation of expression of the AAV gene rep and capsid proteins. Low-level expression of the AAV gene rep protein increases the prodn. of AAV viral capsid protein with a resultant packaging efficiency improvement resulting in prodn. of higher titer recombinant viral stocks. Vectors for rAAV direct the expression of AAV gene rep and capsid proteins and are used for the prodn. of novel stable cell lines capable of generating high-titer rAAV vectors. Methods are described for regulating the expression of the AAV rep gene at the transcriptional and post-translational level. Helper plasmids AAV/Ad, CMV/AAV, HIV/AAV, SV/AAV, and ACG-2 were constructed expressing an entire AAV helper plasmid coding sequence including promoter p5, the same sequence with p5 promoter replaced by cytomegalovirus immediate early promoter, by the HIV long terminal repeat promoter, by the SV40 late promoter, and including the promoter p5 but replacement of the initiation codon ATG with the less efficient codon ACG, resp. Human 293 cells were transfected with different ratios of rAAV vector:helper plasmid. There was efficient gene rep expression from heterologous promoters in the absence of adenovirus. Helper plasmids pCMV/AAV and pHIV/AAV generated the lowest rAAV yields, even though they produced the highest Rep levels. Overexpression of gene rep inhibited rAAV DNA replication and capsid gene expression.

IN Colosi, Peter
SO U.S., 19 pp., Cont.-in-part of Ser. No. US 1998-107708, filed on 30 Jun 1998
CODEN: USXXAM

TI Helper functions for adeno-associated virus for high-efficiency generation of wild-type-free virus carrying foreign genes

AB Helper functions for the packaging of adeno-assocd. virus (AAV) that do not allow the generation pseudowild AAV virions are described. The helper functions include the AAV rep and cap genes expressed from the p19 and p40 promoters but lacking a p5 promoter because of deletion of the p5 TATA box. In addn., inverted terminal repeats are deleted from expression constructs for the rep and cap genes. Host cells expressing these genes and the manuf. of transgenic virions are described. A helper plasmid of the invention, pHLP19, carrying the rep and cap genes and the p19 and p40 promoters gave a yield of AAV that was 200-300% greater than that from prior art helper vectors with no detectable generation of pseudowild type virus.

IN Natsoulis, George; Colosi, Peter; Kurtzman, Gary
SO U.S., 14 pp., Cont.-in-part of U.S. Ser. No. 688,648.
CODEN: USXXAM

TI High-efficiency adeno-associated virus helper functions for improved gene therapy

AB The present invention provides methods and compns. for producing high titer preps. of recombinant AAV ("rAAV") virions. The compns. of the present invention include AAV helper function systems and host cells. The present invention also includes methods of using AAV helper function vectors that effect the prodn. of only small amts. of the long forms of Rep protein, and rAAV virions produced by such methods. Cells transfected with pW1909 comprising rep and cap coding regions and a downstream p5 promoter sandwiched between two Flip Recombination Target (FRT) sites produced very little of the long forms of Rep, as well as more of the short forms of Rep, than other AAV helper function vectors. Introduction of an efficient polyadenylation site between the transcriptional start site and the first codon in the coding sequence of the long forms of Rep protein also decreased expression of the long forms of Rep and

increased expression of the short forms. Prodn. of only small amts. of the long forms of Rep protein provide for higher titer rAAV virion prodn.

- AU Li J; Samulski R J; Xiao X
SO Journal of virology, (1997 Jul) 71 (7) 5236-43.
Journal code: 0113724. ISSN: 0022-538X.
- TI Role for highly regulated rep gene expression in adeno-associated virus vector production.
- AB Recent success achieving long-term in vivo gene transfer without a significant immune response by using adeno-associated virus (AAV) vectors (X. Xiao, J. Li, and R. J. Samulski, J. Virol. 70:8098-8108, 1996) has encouraged further development of this vector for human gene therapy. Currently, studies focus on the generation of high-titer vectors by using the two-plasmid helper-vector system in adenovirus (Ad)-infected cells. To examine the effects of the AAV replication (rep) genes on recombinant AAV (rAAV) vector production, we have constructed a series of AAV helper plasmids that contain strong heterologous promoters in place of the endogenous p5 promoter. Although high-level rep gene expression was achieved, rAAV DNA failed to replicate in the absence of Ad infection. Moreover, unregulated overexpression of Rep78/68 led to substantially lower rAAV yields in the presence of Ad (10(4-5) versus 10(7-8)). In contrast, under similar conditions, reduced Rep78/68 expression resulted in much higher rAAV yields (10(9)). Molecular characterization showed that overexpression of the rep gene decreased rAAV DNA replication and severely inhibited capsid (cap) gene expression. Interestingly, a reduced rep level enhanced cap gene expression and supported normal rAAV DNA replication. These studies suggest a critical role for regulated rep gene expression in rAAV production and have facilitated the development of a new AAV helper plasmid that increases vector production eightfold over currently used constructs.
- AU Conway J E; Zolotukhin S; Muzyczka N; Hayward G S; Byrne B J
SO Journal of virology, (1997 Nov) 71 (11) 8780-9.
Journal code: 0113724. ISSN: 0022-538X.
- TI Recombinant adeno-associated virus type 2 replication and packaging is entirely supported by a herpes simplex virus type 1 amplicon expressing Rep and Cap.
- AB Recombinant adeno-associated virus (AAV) type 2 (rAAV) vectors have recently been shown to have great utility as gene transfer agents both in vitro and in vivo. One of the problems associated with the use of rAAV vectors has been the difficulty of large-scale vector production. Low-efficiency plasmid transfection of the rAAV vector and complementing AAV type 2 (AAV-2) functions (rep and cap) followed by superinfection with adenovirus has been the standard approach to rAAV production. The objectives of this study were to demonstrate the ability of a recombinant herpes simplex virus type 1 (HSV-1) amplicon expressing AAV-2 Rep and Cap to support replication and packaging of rAAV vectors. HSV-1 amplicon vectors were constructed which contain the AAV-2 rep and cap genes under control of their native promoters (p5, p19, and p40). An HSV-1 amplicon vector, HSV-RC/KOS or HSV-RC/d27, was generated by supplying helper functions with either wild-type HSV-1 (KOS strain) or the ICP27-deleted mutant of HSV-1, d27-1, respectively. Replication of the amplicon stocks is not inhibited by the presence of AAV-2 Rep proteins, which highlights important differences between HSV-1 and adenovirus replication and the mechanism of providing helper function for productive AAV infection. Coinfection of rAAV and HSV-RC/KOS resulted in the replication and amplification of rAAV genomes. Similarly, rescue and replication of rAAV genomes occurred when rAAV vector plasmids were transfected into cells followed by HSV-RC/KOS infection and when two rAAV proviral cell lines were infected with HSV-RC/KOS or HSV-RC/d27. Production of infectious rAAV by rescue from two rAAV proviral cell lines has also been achieved with HSV-RC/KOS and HSV-RC/d27. The particle titer of rAAV produced with HSV-RC/d27 is equal to that achieved by supplying rep and cap by transfection followed by adenovirus superinfection. Importantly, no detectable

wild-type AAV-2 is generated with this approach. These results demonstrate that an HSV-1 amplicon expressing the AAV-2 genes rep and cap along with HSV-1 helper functions supports the replication and packaging of rAAV vectors in a scaleable process.

AU Wang X S; Srivastava A
SO Journal of virology, (1998 Jun) 72 (6) 4811-8.
Journal code: 0113724. ISSN: 0022-538X.
TI Rescue and autonomous replication of adeno-associated virus type 2 genomes containing Rep-binding site mutations in the viral p5 promoter.
AB The Rep proteins encoded by the adeno-associated virus type 2 (AAV) play a crucial role in the rescue, replication, and integration of the viral genome. In the absence of a helper virus, little expression of the AAV Rep proteins occurs, and the AAV genome fails to undergo DNA replication. Since previous studies have established that expression of the Rep78 and Rep68 proteins from the viral p5 promoter is controlled by the Rep-binding site (RBS) and the YY1 factor-binding site (YBS), we constructed a number of recombinant AAV plasmids containing mutations and/or deletions of the RBS and the YBS in the p5 promoter. These plasmids were transfected in HeLa or 293 cells and analyzed for the potential to undergo AAV DNA rescue and replication. Our studies revealed that (i) a low-level rescue and autonomous replication of the wild-type AAV genome occurred in 293 but not in HeLa cells; (ii) mutations in the RBS resulted in augmented expression from the p5 promoter, leading to more efficient rescue and/or replication of the AAV genome in 293 but not in HeLa cells; (iii) little rescue and/or replication occurred from plasmids containing mutations in the YBS alone in the absence of coinfection with adenovirus; (iv) expression of the adenovirus E1A gene products was insufficient to mediate rescue and/or replication of the AAV genome in HeLa cells; (v) autonomously replicated AAV genomes in 293 cells were successfully encapsidated in mature progeny virions that were biologically active in secondary infection of HeLa cells in the presence of adenovirus; and (vi) stable transfection of recombinant AAV plasmids containing a gene for resistance to neomycin significantly affected stable integration only in 293 cells, presumably because rescue and autonomous replication of the AAV genome from these plasmids occurred in 293 cells but not in HeLa or KB cells. These data suggest that in the absence of adenovirus, the AAV Rep protein-RBS interaction plays a dominant role in down-regulating viral gene expression from the p5 promoter and that perturbation in this interaction is sufficient to confer autonomous replication competence to AAV in 293 cells.